Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment (PHRC2003)
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country.
Sponsor: Amgen
This observational or N/A phase trial investigates Bladder Disease and Digestive System Diseases and is currently completed. Amgen leads this study, which shows 9 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2022 — Jul 2024 [monthly]
Completed
-
Feb 2022 — Mar 2022 [monthly]
Completed
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Sep 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Aventis Pharmaceuticals
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Institut Bergonié
- Sanofi-Synthelabo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Agen, France , Bayonne, France , Bordeaux, France , Dax, France , Le Bouscat, France , Libourne, France , Mont-de-Marsan, France , Pau, France , Périgueux, France , Talence, France and 1 more location